The XenoMouse That Roared: Cell Genesys' Share Of Abgenix Worth $781 Mil.
Executive Summary
Cell Genesys' 12% share of Abgenix at the end of February is worth more than twice the value of Genzyme's attempted acquisition of Cell Genesys in October.
You may also be interested in...
Novartis Reduces Outsourcing Through Parexel; CRO To Lay Off 400-500
Novartis' cancellation of several outsourcing contracts with Parexel could result in a reduction of the contract research organization's workforce by 400-500 positions, Parexel said.
Amgen Is Biotech Again; Genomic Data Drives Sector To New Highs
Amgen is reclaiming its biotech identity as Wall Street rushes back to biotechnology.
Abgenix Run-Up In Value Ends Cell Genesys/Genzyme Merger
Cell Genesys spin-off Abgenix' success in marketing its XenoMouse technology has helped terminate a proposed merger between Genzyme and Cell Genesys.